INCLUSION CRITERIA - Recipients:
Group A: Patients at high risk for transplant related complications and mortality as defined below:
Ages 10 to 55 (multiple myeloma ages 10 to 65) with a history of one of the following:
-Treatment with dose intensive chemotherapy and/or radiotherapy
-Previous history of allo/auto transplant
-History of multiple myeloma or extramedullary plasmacytoma
-Chronic disease or co-morbid medical condition including patients with symptoms or signs of significant pulmonary disease, hepatic disease, kidney disease, cardiac disease or disease of other organ systems which would result in increased risk of morbidity or death from a standard myeloablative transplant.
Diseases to be included:
-Chronic myelogenous leukemia (CML); chronic phase
-Acute lymphoblastic leukemia (ALL), all patients in complete or partial remission.
-Acute myelogenous leukemia (AML): AML in first complete or partial remission Exceptions: AML with good risk karyotypes: AML M3 t(15:17), AML M4Eo (inv. 16), AML t(8;21). All AML in second or subsequent complete remission.
-Myelodysplastic syndromes: refractory anemia with excess blasts (RAEB), or chronic myelomonocyte leukemia (CMML).
-Myeloproliferative diseases associated with either cytopenia or uncontrolled proliferation.
-Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with bulky or progressive disease despite prior treatment with chemotherapy which includes purine analogs.
-Non-Hodgkin's Lymphoma (NHL)
A) Intermediate or high grade relapsed or progressive despite treatment with standard therapy ineligible for autologous PBSC transplant.
B) Non-Hodgkin's intermediate or high grade relapsing despite prior autologous transplant.
C) Low grade follicular or small lymphocytic lymphoma (1) high risk patients who have relapsed following conventional chemotherapy, (2) relapsed following autologous marrow or PBSC transplant, or (3) chemo resistant disease.
D) Mantle cell lymphoma
-Hodgkin's disease, relapsed after prior autologous transplant or after 2 or more combination chemotherapy regimens and ineligible for autologous PBSC transplant.
-EBV driven lymphoproliferative disorders progressing despite standard therapies.
Group B: Patients with hematologic diseases associated with reasonable longevity, shown to be curable by allogeneic BMT but where concern for a high procedural mortality with conventional BMT may delay or prevent such treatment.
Ages 8 to 80 with a history of one of the following
-Paroxysmal nocturnal hemoglobinuria (PNH) associated with either life-threatening thrombosis, cytopenia, transfusion dependence or recurrent and debilitating hemolytic crisis.
-Aplastic anemia or pure red cell aplasia (acquired or congenital) in patients associated with transfusion dependence and/or neutropenia who are not candidates for or who have failed immunosuppressive therapy
-Refractory anemia (RA) or RARS MDS patients who have associated transfusion dependence and/or neutropenia.
Ability to comprehend the investigational nature of the study and provide informed consent. The procedure will be explained to patients age 8-17 years with formal consent being obtained from parents or legal guardian.
Availability of HLA identical or single HLA locus mismatched family donor
INCLUSION CRITERIA - Donor:
HLA identical or single HLA mismatched family donor
Age greater than or equal to 2 up to 80 years old
Weight greater than or equal to 18 kg
Ability of donor or guardian of donor to comprehend the investigational nature of the study and provide informed consent.
EXCLUSION CRITERIA - Recipient - any of the following:
Pregnant or lactating
Group A: age less than 10 or greater than 55 (multiple myeloma age less than 10 or greater than 65); Group B: Age less than 8 or greater than 80 years.
ECOG performance status of 3 or more. Psychiatric disorder or mental deficiency severe as to make compliance with the BMT treatment unlikely and making informed consent impossible.
Major anticipated illness or organ failure incompatible with survival from PBSC transplant
Diffusion capacity of carbon monoxide (DLCO) less than 40% predicted.
Left ventricular ejection fraction: less than 30%.
Serum creatinine greater than 2.5 mg/dl or creatinine clearance less than 50 cc/min by 24 hr urine collection
Serum bilirubin greater than 4 mg/dl, transaminases greater than 5x upper limit of normal,
Other malignant diseases liable to relapse or progress within 5 years.
EXCLUSION CRITERIA - Donor - any of the following:
Pregnant or lactating
Donor unfit to receive G-CSF and undergo apheresis. (Uncontrolled hypertension, history of congestive heart failure or unstable angina, thrombocytopenia)
HIV positive donor. Donors who are positive for hepatitis B (HBV), hepatitis C (HCV) or human T-cell lymphotropic virus (HTLV I/II) will be used at the discretion of the investigator following counseling and approval from the recipient
National Institutes of Health Clinical Center
Bethesda, Maryland 20892. Last update: 01/13/2009